Heshwin Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Heshwin Singh has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- David A. Chesler
Neurological Surgery, Renaissance School of Medicine at Stony Brook University, Stony Brook, USA
1 shared publication - Emaan Rana
Department of Science University of Western Ontario London Ontario Canada
1 shared publication Emily Bellow
Departments of Neurosurgery, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York
1 shared publication- Justin N. Passman
Renaissance School of Medicine at Stony Brook University
1 shared publication - Magda Wojtara
Department of Research and Education, Oli Health Magazine Organization, Research, and Education, Kigali, Rwanda
1 shared publication - Palak Khanna
Department of Medicine Ivane Javakhishvili Tbilisi State University Tbilisi Georgia
1 shared publication
Latest Publications
- Open Access
- 23 June 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 9 (25)
Recurrent parietal lobe supratentorial ependymoma, ZFTA fusion-positive, CNS WHO grade 3, with new dural and calvarial reactive changes in a child: illustrative case
BACKGROUND: Supratentorial ependymoma, ZFTA fusion-positive, CNS WHO grade 3, is a rare pediatric brain tumor characterized by brisk mitotic activity and sometimes microvascular proliferation and/or necrosis. Typical treatment includes a combination of resection, chemotherapy, and radiation therapy. These tumors often present at age 3 or 4 years and have a poor prognosis. OBSERVATIONS: The authors present the case of a 4-year-old girl who presented asymptomatically with recurrence of a supratentorial ependymoma, ZFTA fusion-positive, CNS WHO grade 3, of the right parietal lobe with a homozygous CDKN2A deletion through chemotherapy after an initial gross-total resection. Tumor recurrence presented with a traditional intraparenchymal cystic component that initially appeared to invade through the dura mater, diploë, and outer table of the skull. On closer examination of the calvaria and dura in the operating room, a trabeculated and soft tissue mixed with invasion into the outer table contiguous with calcifications on the native dura was observed. Histopathological analysis confirmed that the recurrent tumor was confined intradurally with treatment effect, and the dural and calvarial findings represented a reactive inflammatory process likely related to prior surgery, chemotherapy, and possibly the neoplasm itself. LESSONS: This case illustrates an atypical presentation of a recurrent supratentorial ependymoma, ZFTA fusion-positive, CNS WHO grade 3, where reactive inflammatory changes of the dura and calvaria mimicked dural and calvarial invasion. These findings demonstrate the importance of histopathological evaluation in distinguishing true tumor recurrence from atypical inflammatory responses to prior surgery, chemotherapy, or the neoplasm itself and close postoperative follow-up. https://thejns.org/doi/10.3171/CASE25146
- 23 June 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 9 (25)
Open AccessRecurrent parietal lobe supratentorial ependymoma, ZFTA fusion-positive, CNS WHO grade 3, with new dural and calvarial reactive changes in a child: illustrative case
BACKGROUND: Supratentorial ependymoma, ZFTA fusion-positive, CNS WHO grade 3, is a rare pediatric brain tumor characterized by brisk mitotic activity and sometimes microvascular proliferation and/or necrosis. Typical treatment includes a combination of resection, chemotherapy, and radiation therapy. These tumors often present at age 3 or 4 years and have a poor prognosis. OBSERVATIONS: The authors present the case of a 4-year-old girl who presented asymptomatically with recurrence of a supratentorial ependymoma, ZFTA fusion-positive, CNS WHO grade 3, of the right parietal lobe with a homozygous CDKN2A deletion through chemotherapy after an initial gross-total resection. Tumor recurrence presented with a traditional intraparenchymal cystic component that initially appeared to invade through the dura mater, diploë, and outer table of the skull. On closer examination of the calvaria and dura in the operating room, a trabeculated and soft tissue mixed with invasion into the outer table contiguous with calcifications on the native dura was observed. Histopathological analysis confirmed that the recurrent tumor was confined intradurally with treatment effect, and the dural and calvarial findings represented a reactive inflammatory process likely related to prior surgery, chemotherapy, and possibly the neoplasm itself. LESSONS: This case illustrates an atypical presentation of a recurrent supratentorial ependymoma, ZFTA fusion-positive, CNS WHO grade 3, where reactive inflammatory changes of the dura and calvaria mimicked dural and calvarial invasion. These findings demonstrate the importance of histopathological evaluation in distinguishing true tumor recurrence from atypical inflammatory responses to prior surgery, chemotherapy, or the neoplasm itself and close postoperative follow-up. https://thejns.org/doi/10.3171/CASE25146
- Top Cited PapersOpen Access
- 30 August 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (11) , 2106-2111
Artificial intelligence in rare disease diagnosis and treatment
Artificial intelligence (AI) utilization in health care has grown over the past few years. It also has demonstrated potential in improving the efficiency of diagnosis and treatment. Some types of AI, such as machine learning, allow for the efficient analysis of vast datasets, identifying patterns, and generating key insights. Predictions can then be made for medical diagnosis and personalized treatment recommendations. The use of AI can bypass some conventional limitations associated with rare diseases. Namely, it can optimize traditional randomized control trials, and may eventually reduce costs for drug research and development. Recent advancements have enabled researchers to train models based on large datasets and then fine‐tune these models on smaller datasets typically associated with rare diseases. In this mini‐review, we discuss recent advancements in AI and how AI can be applied to streamline rare disease diagnosis and optimize treatment.
- 30 August 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (11) , 2106-2111
Top Cited PapersOpen AccessArtificial intelligence in rare disease diagnosis and treatment
Artificial intelligence (AI) utilization in health care has grown over the past few years. It also has demonstrated potential in improving the efficiency of diagnosis and treatment. Some types of AI, such as machine learning, allow for the efficient analysis of vast datasets, identifying patterns, and generating key insights. Predictions can then be made for medical diagnosis and personalized treatment recommendations. The use of AI can bypass some conventional limitations associated with rare diseases. Namely, it can optimize traditional randomized control trials, and may eventually reduce costs for drug research and development. Recent advancements have enabled researchers to train models based on large datasets and then fine‐tune these models on smaller datasets typically associated with rare diseases. In this mini‐review, we discuss recent advancements in AI and how AI can be applied to streamline rare disease diagnosis and optimize treatment.